BRPI0821454B8 - formulação farmacêutica, mistura de glicogênio, alginato e sais de metais alcalino terrosos, processos para a produção de um excipiente de liberação lenta, e de uma forma farmacêutica - Google Patents
formulação farmacêutica, mistura de glicogênio, alginato e sais de metais alcalino terrosos, processos para a produção de um excipiente de liberação lenta, e de uma forma farmacêuticaInfo
- Publication number
- BRPI0821454B8 BRPI0821454B8 BRPI0821454A BRPI0821454A BRPI0821454B8 BR PI0821454 B8 BRPI0821454 B8 BR PI0821454B8 BR PI0821454 A BRPI0821454 A BR PI0821454A BR PI0821454 A BRPI0821454 A BR PI0821454A BR PI0821454 B8 BRPI0821454 B8 BR PI0821454B8
- Authority
- BR
- Brazil
- Prior art keywords
- slow
- glycogen
- alginate
- earth metal
- alkaline earth
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 239000000546 pharmaceutical excipient Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 title abstract 3
- 229920002527 Glycogen Polymers 0.000 title abstract 3
- 229940072056 alginate Drugs 0.000 title abstract 3
- 235000010443 alginic acid Nutrition 0.000 title abstract 3
- 229920000615 alginic acid Polymers 0.000 title abstract 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 title abstract 3
- -1 alkaline earth metal salts Chemical class 0.000 title abstract 3
- 229940096919 glycogen Drugs 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
formulação farmacêutica, excipiente para a preparação de formulações farmacêuticas de liberação lenta, e, processos para a produção de um excipiente de liberação lenta, e de uma forma farmacêutica a presente invenção refere-se a uma formulação farmacêutica de liberação controlada, que compreende pelo menos um ingrediente ativo dispersado em uma matriz, que compreende pelo menos um excipiente de liberação lenta em associação com pelo menos um glicogênio e pelo menos um alginato com sais de metais alcalino terrosos, e a um processo para a sua preparação. a invenção também se refere a um excipiente de liberação lenta, que compreende uma associação de pelo menos um glicogênio e de pelo menos um alginato com sais de metais alcalino terrosos, e a um processo para a sua preparação, e a seu uso para a preparação de formulações farmacêuticas de liberação lenta.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07425828 | 2007-12-28 | ||
| PCT/EP2008/068256 WO2009083561A1 (en) | 2007-12-28 | 2008-12-23 | A slow-release formulation based on an association of glycogen and alginate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0821454A2 BRPI0821454A2 (pt) | 2015-06-16 |
| BRPI0821454B1 BRPI0821454B1 (pt) | 2020-01-28 |
| BRPI0821454B8 true BRPI0821454B8 (pt) | 2021-05-25 |
Family
ID=39522216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0821454A BRPI0821454B8 (pt) | 2007-12-28 | 2008-12-23 | formulação farmacêutica, mistura de glicogênio, alginato e sais de metais alcalino terrosos, processos para a produção de um excipiente de liberação lenta, e de uma forma farmacêutica |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8840923B2 (pt) |
| EP (1) | EP2234607B1 (pt) |
| JP (1) | JP5416716B2 (pt) |
| KR (1) | KR101561571B1 (pt) |
| CN (1) | CN101909608B (pt) |
| AR (1) | AR069960A1 (pt) |
| AT (1) | ATE518530T1 (pt) |
| AU (1) | AU2008342571B2 (pt) |
| BR (1) | BRPI0821454B8 (pt) |
| CA (1) | CA2708400C (pt) |
| DK (1) | DK2234607T3 (pt) |
| EA (1) | EA018975B1 (pt) |
| ES (1) | ES2369868T3 (pt) |
| GE (1) | GEP20125636B (pt) |
| IL (1) | IL206124A (pt) |
| PL (1) | PL2234607T3 (pt) |
| PT (1) | PT2234607E (pt) |
| SI (1) | SI2234607T1 (pt) |
| UA (1) | UA98684C2 (pt) |
| WO (1) | WO2009083561A1 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG171444A1 (en) | 2009-01-23 | 2011-07-28 | Acraf | Controlled release pharmaceutical or food formulation and process for its preparation |
| JP5639649B2 (ja) * | 2009-08-03 | 2014-12-10 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニＡｚｉｅｎｄｅ Ｃｈｉｍｉｃｈｅ Ｒｉｕｎｉｔｅ Ａｎｇｅｌｉｎｉ Ｆｒａｎｃｅｓｃｏ Ａ．Ｃ．Ｒ．Ａ．Ｆ．Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ | グリコーゲンを含む食品製剤 |
| KR102214865B1 (ko) * | 2013-04-26 | 2021-02-15 | 마이렉서스 바이오테크놀로지스 인코퍼레이티드 | 파이토글리코겐 나노입자와 이를 제조하는 방법 |
| CN106137977B (zh) * | 2015-04-28 | 2019-12-13 | 浙江普利药业有限公司 | 海参多糖肠溶微丸及其制备方法 |
| US11865099B2 (en) | 2015-07-17 | 2024-01-09 | Laboratori Baldacci S.P.A. | Product based on iron bis-glycinate chelate and alginic acid and/or water-soluble salts thereof, formulations thereof, and pharmaceutical uses thereof |
| ITUB20152290A1 (it) * | 2015-07-17 | 2017-01-17 | Laboratori Baldacci Spa | Prodotto a base di ferro bisglicinato chelato e acido alginico e/o suoi sali idrosolubili, sue formulazioni ed suoi usi farmaceutici |
| EP3413866A4 (en) * | 2016-02-08 | 2019-07-17 | Mirexus Biotechnologies Inc. | MOISTURIZING BODY CARE COMPOSITIONS WITH MONODISPERSES PHYTOGLYCOGENNANOPARTICLES AND ANOTHER POLYSACCHARIDE |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3640741A (en) * | 1970-02-24 | 1972-02-08 | Hollister Inc | Composition containing gel |
| DE2062715C3 (de) * | 1970-12-19 | 1974-03-21 | Efeka Friedrich & Kaufmann Arzneimittelfabrik, 3000 Hannover | Verfahren zur Herstellung von oral applizierbaren Arzneimittelzubereitungen mit protrahierter Wirkstoffabgabe und Arzneimittelzubereitung |
| ATE66143T1 (de) * | 1985-01-11 | 1991-08-15 | Abbott Lab | Feste zubereitung mit langsamer freisetzung. |
| JPS62178505A (ja) | 1986-02-03 | 1987-08-05 | Maruzen Kasei Kk | 化粧料 |
| JPS63290809A (ja) | 1987-05-25 | 1988-11-28 | Noebia:Kk | 口唇用化粧料 |
| CA2041774C (en) * | 1990-11-27 | 1994-04-19 | Mircea A. Mateescu | Use of cross-linked amylose as a matrix for the slow release of biologically active compounds |
| IT1255488B (it) | 1992-08-04 | 1995-11-06 | Angelini Francesco Ist Ricerca | Polisaccaridi del glicogeno |
| US5705190A (en) * | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
| US5807575A (en) | 1997-02-14 | 1998-09-15 | Rougier Inc. | Manufacture of cross-linked amylose useful as a excipient for control release of active compounds |
| IT1298758B1 (it) | 1998-03-19 | 2000-02-02 | Angelini Ricerche Spa | Soluzione umettante e lubrificante per uso oftalmico |
| US6607748B1 (en) * | 2000-06-29 | 2003-08-19 | Vincent Lenaerts | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture |
| AU2001227030A1 (en) * | 2000-11-22 | 2002-06-03 | Lupin Laboratories Limited | Pharmaceutical composition for controlled release of an active ingredient |
| WO2004096127A2 (en) * | 2003-04-25 | 2004-11-11 | Kos Life Sciences, Inc. | Formation of strong superporous hydrogels |
| US20060067917A1 (en) * | 2004-09-20 | 2006-03-30 | Athanassios Sambanis | Insulin delivery system |
| WO2007047922A2 (en) * | 2005-10-19 | 2007-04-26 | Smartcells, Inc. | Polymer-drug conjugates |
-
2008
- 2008-12-23 AR ARP080105697A patent/AR069960A1/es not_active Application Discontinuation
- 2008-12-23 PL PL08867925T patent/PL2234607T3/pl unknown
- 2008-12-23 WO PCT/EP2008/068256 patent/WO2009083561A1/en not_active Ceased
- 2008-12-23 GE GEAP200811898A patent/GEP20125636B/en unknown
- 2008-12-23 US US12/745,816 patent/US8840923B2/en not_active Expired - Fee Related
- 2008-12-23 DK DK08867925.3T patent/DK2234607T3/da active
- 2008-12-23 CA CA2708400A patent/CA2708400C/en not_active Expired - Fee Related
- 2008-12-23 CN CN2008801227782A patent/CN101909608B/zh not_active Expired - Fee Related
- 2008-12-23 PT PT08867925T patent/PT2234607E/pt unknown
- 2008-12-23 SI SI200830407T patent/SI2234607T1/sl unknown
- 2008-12-23 UA UAA201007866A patent/UA98684C2/uk unknown
- 2008-12-23 KR KR1020107015913A patent/KR101561571B1/ko not_active Expired - Fee Related
- 2008-12-23 EA EA201070806A patent/EA018975B1/ru not_active IP Right Cessation
- 2008-12-23 AU AU2008342571A patent/AU2008342571B2/en not_active Ceased
- 2008-12-23 AT AT08867925T patent/ATE518530T1/de active
- 2008-12-23 JP JP2010540124A patent/JP5416716B2/ja not_active Expired - Fee Related
- 2008-12-23 EP EP08867925A patent/EP2234607B1/en active Active
- 2008-12-23 BR BRPI0821454A patent/BRPI0821454B8/pt not_active IP Right Cessation
- 2008-12-23 ES ES08867925T patent/ES2369868T3/es active Active
-
2010
- 2010-06-01 IL IL206124A patent/IL206124A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| IL206124A (en) | 2013-01-31 |
| ATE518530T1 (de) | 2011-08-15 |
| AU2008342571B2 (en) | 2014-03-13 |
| UA98684C2 (uk) | 2012-06-11 |
| SI2234607T1 (sl) | 2011-11-30 |
| CN101909608A (zh) | 2010-12-08 |
| BRPI0821454B1 (pt) | 2020-01-28 |
| US8840923B2 (en) | 2014-09-23 |
| KR101561571B1 (ko) | 2015-10-19 |
| ES2369868T3 (es) | 2011-12-07 |
| BRPI0821454A2 (pt) | 2015-06-16 |
| PL2234607T3 (pl) | 2011-12-30 |
| CA2708400A1 (en) | 2009-07-09 |
| EA018975B1 (ru) | 2013-12-30 |
| CA2708400C (en) | 2016-02-02 |
| EP2234607A1 (en) | 2010-10-06 |
| WO2009083561A1 (en) | 2009-07-09 |
| AU2008342571A1 (en) | 2009-07-09 |
| JP5416716B2 (ja) | 2014-02-12 |
| IL206124A0 (en) | 2010-11-30 |
| GEP20125636B (en) | 2012-09-10 |
| AR069960A1 (es) | 2010-03-03 |
| KR20100099728A (ko) | 2010-09-13 |
| HK1145284A1 (en) | 2011-04-15 |
| US20100255083A1 (en) | 2010-10-07 |
| JP2011519820A (ja) | 2011-07-14 |
| CN101909608B (zh) | 2013-01-23 |
| DK2234607T3 (da) | 2011-11-21 |
| EP2234607B1 (en) | 2011-08-03 |
| EA201070806A1 (ru) | 2010-12-30 |
| PT2234607E (pt) | 2011-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0812064B8 (pt) | formulação farmacêutica na forma de aglomerados, comprimidos, e, processo para a produção de uma formulação farmacêutica | |
| DOP2011000094A (es) | Formulacion farmaceutica 514 | |
| AR134222A2 (es) | Un proceso para preparar una composición de comprimido adecuada para el tratamiento de trastornos mediados por la actividad de la tirosina cinasa de bruton | |
| AR081760A1 (es) | Una composicion farmaceutica para administracion oral que comprende acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico, un metodo para producir la misma, una tableta y una forma unitaria de dosificacion oral que la comprende y el uso de la misma para la fabricacion de un medicamento | |
| BRPI0922796A2 (pt) | Comprimido farmacêutico para administração por via oral e método de fabricação do mesmo | |
| UY29410A1 (es) | Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones. | |
| ECSP077999A (es) | Formulaciones de una sal de bupropion de liberación modificada | |
| BR112014011841A2 (pt) | material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos | |
| BR112012023324B8 (pt) | processo de preparação de uma forma de dosagem multifásica liofilizada de dissolução rápida | |
| BRPI0720588B8 (pt) | derivados de pirazol-quinazolina substituídos, processo para sua preparação e seu uso como inibidores da quinase | |
| CL2010001275A1 (es) | Metodo para producir un producto intermedio compactado de bibw 2992 ma2 que comprende una etapa de compactacion por rodillos de bibw 2992 ma2 u opcionalmente en una premezcla con 0-1,0% de lubricante en un mezclador de caida libre o de volteo y una etapa de tamizado; producto intermedio compactado; comprimido. | |
| BR112022012063A2 (pt) | Comprimidos de edoxabana | |
| BRPI0707044B8 (pt) | comprimido matricial insolúvel em água e processo de fabricação de comprimidos matriciais | |
| MX2011007817A (es) | Formulacion farmaceutica o alimenticia de liberacion controlada y proceso para su preparacion. | |
| BR122019027412B8 (pt) | composição farmacêutica de liberação sustentada na forma de micropartículas, processo para preparação das ditas micropartículas, e kit de administração | |
| BRPI0620185B8 (pt) | formulação farmacêutica, comprimidos, e, processo para a preparação de uma formulação farmacêutica | |
| ATE494889T1 (de) | Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol | |
| BRPI0914225A8 (pt) | Método de preparação de uma composição farmacêutica de formas galênicas de liberação controlada de relaxantes do músculo-esquelético | |
| BR112015001640A2 (pt) | formulações e métodos de produção de formulações para uso em evacuação colônica | |
| BR112018072113A2 (pt) | excipiente à base de proteínas para ingredientes farmacêuticos ativos | |
| BRPI0909211B8 (pt) | formulação oral em forma de comprimido de compostos de tetraciclina | |
| GEP20125636B (en) | Slow-release formulation based on glycogen and alginate association | |
| DE602006016127D1 (de) | Zusammensetzung und dosierform mit einer festen oder halbfesten matrix | |
| AR060869A1 (es) | Composicion farmaceutica solida de gabapentina | |
| BRPI0513938A (pt) | composição farmacêutica contendo drospirenona e etinilestradiol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B09X | Republication of the decision to grant [chapter 9.1.3 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/01/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 13A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2650 DE 19-10-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |